Mycobacterial Infections Potentiated by Biologics

Cassandra Calabrese, Kevin L. Winthrop

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Biologic therapies have revolutionized the treatment of immune-mediated inflammatory diseases but are associated with an increased risk of serious and opportunistic infections, including tuberculosis and nontuberculous mycobacterial disease. Despite this increased risk, the overall risk-benefit ratio remains favorable with appropriate screening and risk assessment. Further population-based studies are needed to establish the risk of tuberculosis and nontuberculous mycobacterial disease with the new biologics. This article highlights the incidence and drug-specific risk of tuberculous and nontuberculous mycobacterial infection in the setting of biologics, screening and prevention, and treatment of latent tuberculosis in this setting.

Original languageEnglish (US)
Pages (from-to)413-423
Number of pages11
JournalInfectious Disease Clinics of North America
Issue number2
StatePublished - Jun 2020


  • Biologics
  • Mycobacteria
  • Opportunistic infection
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Mycobacterial Infections Potentiated by Biologics'. Together they form a unique fingerprint.

Cite this